<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        120-368-09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MAXIM 400MG FILM COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIFLOXACIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        80.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Maxim&trade; contains the active substance moxifloxacin, which belongs to a group of<br />antibiotics called fluoroquinolones. Maxim&trade; works by killing bacteria that cause<br />infections.<br />Maxim&trade; is used in patients aged 18 years and above for treating the following<br />bacterial infections when caused by bacteria against which moxifloxacin is active.<br />Maxim&trade; should only be used to treat these infections when usual antibiotics cannot<br />be used or have not worked:<br />Infection of the sinuses, sudden worsening of long term inflammation of the airways<br />or infection of the lungs (pneumonia) acquired outside the hospital (except severe<br />cases).<br />Mild to moderate infections of the female upper genital tract (pelvic inflammatory<br />disease), including infections of the fallopian tubes and infections of the uterus<br />mucous membrane.<br />Maxim&trade; tablets are not sufficient on their own for treating this kind of infection.<br />Therefore, another antibiotic in addition to Maxim&trade; tablets should be prescribed by<br />your doctor for the treatment of infections of the female upper genital tract<br />(see section 2. Before you take Maxim&trade;, Warnings and precautions, Talk to your<br />doctor before taking Maxim&trade;).<br />If the following bacterial infections have shown improvement during initial treatment<br />with moxifloxacin solution for infusion, Maxim&trade; tablets may also be prescribed by<br />your doctor to complete the course of therapy:<br />Infection of the lungs (pneumonia) acquired outside the hospital, infections of the<br />skin and soft tissue. Maxim&trade; tablets should not be used to initiate therapy for any<br />type of infections of the skin and soft tissue or in severe infections of the lungs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contact your doctor if you are not sure if you belong to a patient group described<br />below.<br />Do not take Maxim&trade;<br />- If you are allergic to the active substance moxifloxacin, any other quinolone<br />antibiotics or any of the other ingredients of this medicine (listed in section 6. Further<br />information).<br />- If you are pregnant or are breast-feeding.<br />- If you are under 18 years of age.<br />- If you have previously had problems with your tendons related to treatment with<br />quinolone antibiotics (see section Warnings and Precautions &hellip; and section<br />4. Possible side effects).<br />- If you were born with or have.<br />&bull; any condition with abnormal heart rhythm (seen on ECG, electrical recording of the<br />heart).<br />&bull; a salt imbalance in the blood (especially low levels of potassium or magnesium in<br />the blood).<br />&bull; a very slow heart rhythm (called &lsquo;bradycardia&rsquo;).<br />&bull; a weak heart (heart failure).<br />&bull; a history of abnormal heart rhythms.<br />or<br />&bull; if you are taking other medicines that result in abnormal ECG changes (see section<br />Other medicines and Maxim&trade;). This is because Maxim&trade; can cause changes on the<br />ECG, that is a prolongation of the QT-interval, i.e., delayed conduction of electrical<br />signals.<br />- If you have a severe liver disease or increased liver enzymes (transaminases) higher<br />than 5 times the upper normal limit.<br />Warnings and precautions<br />Talk to your doctor before taking Maxim&trade;<br />- If you have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic<br />aneurysm or large vessel peripheral aneurysm).<br />- If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).<br />- If you have family history of aortic aneurysm or aortic dissection or other risk factors or<br />predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular<br />Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis,<br />Behcet&rsquo;s disease, high blood pressure, or know atherosclerosis).<br />If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an<br />emergency room.<br />- Maxim&trade; can change your heart&rsquo;s ECG, especially if you are female, or if you are<br />elderly. If you are currently taking any medicine that decreases your blood potassium<br />levels, consult your doctor before taking Maxim&trade; (see also sections Do not take and<br />Other medicines and Maxim&trade;).<br />- If you suffer from epilepsy or a condition which makes you likely to have<br />convulsions talk to your doctor before taking Maxim&trade;.<br />- If you have or have ever had any mental health problems, consult your doctor<br />before taking Maxim&trade;.<br />- If you suffer from myasthenia gravis (abnormal muscle fatigue leading to<br />weakness and in serious cases paralysis), taking Maxim&trade; may worsen the symptoms<br />of your disease. If you think you are affected consult your doctor immediately.<br />- If you or any member of your family have glucose-6-phosphate dehydrogenase<br />deficiency (a rare hereditary disease), tell your doctor, who will advise whether<br />Maxim&trade; is suitable for you.<br />- If you have a complicated infection of the female upper genital tract (e.g.<br />associated with an abscess of the fallopian tubes and ovaries or of the pelvis), for<br />which your doctor considers an intravenous treatment necessary, treatment with<br />Maxim&trade; tablets is not appropriate.<br />- For the treatment of mild to moderate infections of the female upper genital<br />tract your doctor should prescribe another antibiotic in addition to Maxim&trade;. If there<br />is no improvement in symptoms after 3 days of treatment, please consult your doctor.<br />When taking Maxim&trade;<br />- If you experience palpitations or irregular heart beat during the period of<br />treatment, you should inform your doctor immediately. He/she may wish to perform<br />an ECG to measure your heart rhythm.<br />- The risk of heart problems may increase with increase of the dose. Therefore, the<br />recommended dosage should be followed.<br />- There is a rare chance that you may experience a severe, sudden allergic reaction<br />(an anaphylactic reaction/shock) even with the first dose. Symptoms include tightness<br />in the chest, feeling dizzy, feeling sick or faint, or dizziness when standing up. If so,<br />stop taking Maxim&trade; and seek medical advice immediately.<br />- Maxim&trade; may cause a rapid and severe inflammation of the liver which could<br />lead to life-threatening liver failure (including fatal cases, see section 4. Possible side<br />effects). If you suddenly feel unwell and/or are being sick and also have yellowing of<br />the whites of the eyes, dark urine, itching of the skin, a tendency to bleed or liver<br />induced disease of the brain (symptoms of a reduced liver function or a rapid and<br />severe inflammation of the liver) please contact your doctor before taking any more<br />tablets.<br />- If you develop a skin reaction or blistering / peeling of the skin and/or mucosal<br />reactions (see section 4. Possible side effects) contact your doctor immediately<br />before you continue treatment.<br />- Quinolone antibiotics, including Maxim&trade;, may cause convulsions. If this happens,<br />stop taking Maxim&trade; and contact your doctor immediately.<br />- Peripheral neuropathies have been associated with fluoroquinolones use including<br />Maxim&trade; that symptoms may occur soon after initiation of therapy and may be<br />irreversible. If symptoms of peripheral neuropathy including pain, burning, tingling,<br />numbness and/or weakness develop, you should immediately discontinue Maxim&trade;<br />and contact your doctor.<br />- You may experience mental health problems even when taking quinolone<br />antibiotics, including MaximTM, for the first time. In very rare cases depression or<br />mental health problems have led to suicidal thoughts and self-injurious behavior such<br />as suicide attempts (see section 4. Possible side effects). If you develop such<br />reactions, stop taking Maxim&trade; and inform your doctor immediately.<br />- You may develop diarrhoea whilst or after taking antibiotics including MaximTM.<br />If this becomes severe or persistent or you notice that your stool contains blood or<br />mucus you should stop taking Maxim&trade; immediately and consult your doctor.<br />You should not take medicines that stop or slow down bowel movement.<br />&bull; Maxim&trade; may cause pain and inflammation of your tendons, even within 48 hours<br />of starting treatment and up to several months after discontinuing Maxim&trade; therapy.<br />The risk of inflammation and rupture of tendons is increased if you are elderly or if<br />you are also taking corticosteroids. At the first sign of any pain or inflammation you<br />should stop taking Maxim&trade;, rest the affected limb(s) and consult your doctor<br />immediately. Avoid any unnecessary exercise, as this might increase the risk of a<br />tendon rupture (see sections Do not take Maxim&trade; and 4. Possible side effects).<br />- If you are elderly and have kidney problems make sure that you drink plenty<br />whilst taking Maxim&trade;. If you get dehydrated this may increase the risk of kidney<br />failure.<br />- If your eyesight becomes impaired or if your eyes seem to be affected whilst taking<br />Maxim&trade;, consult an eye specialist immediately (see sections Driving and using<br />machines and 4. Possible side effects).<br />- Quinolone antibiotics may make your skin become more sensitive to sunlight or<br />UV light. You should avoid prolonged exposure to sunlight or strong sunlight and<br />should not use a sunbed or any other UV lamp while taking Maxim&trade;.<br />- The efficacy of MaximTM in the treatment of severe burns, infections of deep tissue<br />and diabetic foot infections with osteomyelitis (infections of the bone marrow) has<br />not been established.<br />Children and adolescents<br />Do not give this medicine to children and adolescents under the age of 18 because<br />efficacy and safety have not been established for this age group (see section Do not<br />take Maxim&trade;).<br />Other medicines and Maxim&trade;<br />Tell your doctor or pharmacist about any other medicines that you are taking, took<br />recently or might take.<br />For Maxim&trade;, be aware of the following:<br />- If you are taking MaximTM and other medicines that affect your heart there is an<br />increased risk for altering your heart rhythm. Therefore, do not take MaximTM<br />together with the following medicines:<br />&bull; medicines that belong to the group of anti-arrhythmics (e.g. quinidine,<br />hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide and ibutilide).<br />&bull; antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)<br />&bull; tricyclic antidepressants.<br />&bull; some antimicrobials (e.g. saquinavir, sparfloxacin, intravenous erythromycin,<br />pentamidine and antimalarials particularly halofantrine).<br />&bull; some antihistamines (e.g. terfenadine, astemizole and mizolastine).<br />&bull; other medicines (e.g. cisapride, intravenous vincamine, bepridil and diphemanil).<br />- You must tell your doctor if you are taking other medicines that can lower your<br />blood potassium levels (e.g. some diuretics, some laxatives and enemas [high doses]<br />or corticosteroids [anti-inflammatory drugs], amphotericin B) or cause a slow heart<br />rate because these can also increase the risk of serious heart rhythm disturbances<br />while taking Maxim&trade;.<br />- Any medicine containing magnesium or aluminium (such as antacids for<br />indigestion), iron, zinc or didanosine or any medicine containing sucralfate (to<br />treat stomach disorders) can reduce the action of Maxim&trade; tablets. Take your Maxim<br />&trade; tablet 6 hours before or after taking the other medicine.<br />- Taking any medicine containing charcoal at the same time as Maxim&trade; tablets<br />reduces the action of Maxim&trade;. It is recommended that these medicines are not used<br />together.<br />- If you are currently taking drugs to thin your blood (oral anti-coagulants such as<br />warfarin), it may be necessary for your doctor to monitor your blood clotting time.<br />Maxim&trade; with food and drink<br />Maxim&trade; can be taken with or without food (including dairy products).<br />Pregnancy, breast-feeding and fertility<br />Do not take Maxim&trade; if you are pregnant or breast-feeding.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Animal studies do not indicate that your fertility will be impaired by taking this<br />medicine.<br />Driving and using machines<br />Maxim&trade; may make you feel dizzy or light-headed, you may experience a sudden,<br />transient loss of vision, or you may faint for a short period. If you are affected do not<br />drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check<br />with your doctor or pharmacist if you are not sure.<br />The recommended dose for adults is one 400 mg film-coated tablet once daily.<br />Maxim&trade; tablets are for oral use. Swallow the tablet whole (to mask the bitter taste)<br />and with plenty of liquid. You can take Maxim&trade; with or without food. Try to take the<br />tablet at approximately the same time each day.<br />The same dose can be taken by elderly patients, patients with a low body weight or in<br />patients with kidney problems.<br />The time you will take Maxim&trade; for depends on your infection. Unless your doctor<br />tells you otherwise, your treatment will be as follows:<br />- for sudden worsening (acute exacerbation) of chronic bronchitis 5 - 10 days.<br />- for infection of the lungs (pneumonia) except for pneumonia which starts during a<br />stay in hospital 10 days.<br />- for acute infection of the sinuses (acute bacterial sinusitis) 7 days.</p><p>- Mild to moderate infections of the female upper genital tract (pelvic inflammatory<br />disease), including infection of the fallopian tubes and infection of the uterus mucous<br />membrane 14 days.<br />When Maxim&trade; film-coated tablets are used to complete a course of therapy started<br />with moxifloxacin solution for infusion, the recommended durations of use are:<br />- Infection of the lungs (pneumonia) acquired outside the hospital 7 -14 days.<br />Most patients with pneumonia were switched to oral treatment with Maxim&trade;<br />film-coated tablets within 4 days.<br />- Infections of the skin and soft tissue 7 -21 days.<br />Most patients with infections of the skin and soft tissue were switched to oral<br />treatment with Maxim&trade; film-coated tablets within 6 days.<br />It is important that you complete the course of treatment even if you begin to feel<br />better after a few days. If you stop taking Maxim&trade; too soon your infection may not be<br />completely cured and the infection may return or your condition may get worse. The<br />bacteria causing your infection may become resistant to Maxim&trade;.<br />The recommended dose and duration of treatment should not be exceeded (see section<br />2. Before you take Maxim&trade;, Warnings and precautions).<br />If you take more Maxim&trade; than you should<br />If you take more than the prescribed one tablet a day, get medical help immediately.<br />Try to take any remaining tablets, the packaging or this leaflet with you to show the<br />doctor or pharmacist what you have taken.<br />If you forget to take Maxim&trade;<br />If you forget to take your tablet you should take it as soon as you remember on the<br />same day. If you do not remember on the same day, take your normal dose (one<br />tablet) on the next day. Do not take a double dose to make up for a forgotten dose.<br />If you are unsure about what to do ask your doctor or pharmacist.<br />If you stop taking Maxim&trade;<br />If you stop taking this medicine too soon your infection may not be completely cured.<br />Talk to your doctor if you wish to stop taking your tablets before the end of the<br />course of treatment.<br />If you have any further questions about this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them. The following side effects have been observed during treatment with<br />MaximTM. The frequency of possible side effects listed below is defined using the<br />following convention:<br />Common: may affect up to 1 in 10 people.<br />Uncommon: may affect up to 1 in 100 people.<br />Rare: may affect up to 1 in 1,000 people.<br />Very rare: may affect up to 1 in 10,000 people.<br />Cardiac System (see section 2. Before you take MaximTM)<br />Common: Change of the heart rhythm (ECG) in patients with low blood potassium<br />level.<br />Uncommon: Change of the heart rhythm (ECG), palpitations, irregular and fast<br />heartbeat, severe heart rhythm abnormalities, chest pain (angina pectoris).<br />Rare: Abnormal fast heart rhythm, fainting.<br />Very rare: Abnormal heart rhythms, life-threatening irregular heartbeat, stopping of<br />heartbeat.<br />Common side effects:<br />&bull; Infections caused by resistant bacteria or fungi, e.g. oral and vaginal infections<br />caused by Candida (thrush).<br />&bull; Headache.<br />&bull; Dizziness.<br />&bull; Feeling sick (nausea).<br />&bull; Being sick (vomiting).<br />&bull; Stomach ache.<br />&bull; Diarrhoea.<br />&bull; Increase of a special liver enzyme in the blood (transaminases).<br />Uncommon side effects:<br />&bull; Allergic reaction.<br />&bull; Low red blood cell count (anaemia).<br />&bull; Low white blood cells count.<br />&bull; Low numbers of special white blood cells (neutrophils).<br />&bull; Decrease or increase of special blood cells necessary for blood clotting.<br />&bull; Increased specialised white blood cells (eosinophils).<br />&bull; Decreased blood clotting.<br />&bull; Increased blood lipids (fats).<br />&bull; Feeling anxious, restless, or agitated.<br />&bull; Tingling sensation (pins and needles) and/or numbness.<br />&bull; Changes in taste (in very rare cases loss of taste).<br />&bull; Feeling confused and disorientated.<br />&bull; Sleep problems (e.g. sleeplessness or sleepiness).<br />&bull; Shaking.<br />&bull; Sensation of dizziness (spinning or falling over).<br />&bull; Problems with vision (including double or blurred vision).<br />&bull; Widening of the blood vessels (flushing).<br />&bull; Difficulty in breathing (including asthmatic conditions).<br />&bull; Decreased appetite and food intake.<br />&bull; Wind and constipation.<br />&bull; Stomach upset (indigestion or heartburn).<br />&bull; Inflammation of the stomach.<br />&bull; Increase of a special digestive enzyme in the blood (amylase).<br />&bull; Problems with liver function (including increase of a special liver enzyme in the<br />blood (LDH)), increase of bilirubin in the blood, increase of a special liver enzyme in<br />the blood (gamma-glutamyl-transferase and/or alkaline phosphatase).<br />&bull; Itching, rash, skin hives, dry skin.<br />&bull; Joint pain, muscle pain.<br />&bull; Dehydration.<br />&bull; Feeling unwell (usually weakness or tiredness), aches and pains such as back, chest,<br />pelvic pains and pains in the extremities.<br />&bull; Sweating.<br />Rare side effects:<br />&bull; Severe, sudden allergic reaction including very rarely life-threatening shock (e.g.<br />difficulty in breathing, drop of blood pressure, fast pulse), swelling (including<br />potentially life-threatening swelling of the airway).<br />&bull; Severe diarrhoea containing blood and/or mucus (antibiotic associated colitis<br />including pseudomembranous colitis), which very rarely, may develop into<br />complications that are life-threatening.<br />&bull; Jaundice (yellowing of the whites of the eyes or skin), inflammation of the liver.<br />&bull; Pain and swelling of the tendons (tendonitis).<br />&bull; Increased blood sugar.<br />&bull; Increased blood uric acid.<br />&bull; Feeling particularly emotional.<br />&bull; Depression (which in very rare cases may lead to self-harm, such as suicidal<br />ideations/thoughts, or suicide attempts).<br />&bull; Hallucination.<br />&bull; Problems with skin sensations.<br />&bull; Changes in smell (including loss of smell).<br />&bull; Unusual dreams.<br />&bull; Problems with balance and co-ordination (due to dizziness).<br />&bull; Convulsions.<br />&bull; Disturbed concentration.<br />&bull; Problems with speech.<br />&bull; Partial or total loss of memory.<br />&bull; Troubles associated with the nervous system such as pain, burning, tingling,<br />numbness and/or weakness in extremities.<br />&bull; Ringing or noise in the ears, hearing impairment including deafness (usually<br />reversible).<br />&bull; High or low blood pressure.<br />&bull; Difficulty in swallowing.<br />&bull; Inflammation of the mouth.<br />&bull; Muscle cramps or twitching.<br />&bull; Muscle weakness.<br />&bull; Kidney problems (including an increase in special kidney laboratory test results like<br />urea and creatinine), kidney failure.<br />&bull; Swelling (of the hands, feet, ankles, lips, mouth or throat).<br />Very rare side effects:<br />&bull; Severe inflammation of the liver potentially leading to life-threatening liver failure<br />(including fatal cases).<br />&bull; Changes to the skin and mucous membranes (painful blisters in the mouth/nose or at<br />the penis/vagina), potentially life-threatening (Stevens-Johnson-Syndrome, toxic<br />epidermal necrolysis).<br />&bull; Rupture of tendons.<br />&bull; Increased blood clotting, significant decrease of special white blood cells<br />(agranulocytosis).<br />&bull; A feeling of self-detachment (not being yourself).<br />&bull; Feeling mentally unwell (potentially leading to self-harm, such as suicidal<br />ideations/thoughts, or suicide attempts).<br />&bull; Transient loss of vision.<br />&bull; Skin feeling more sensitive.<br />&bull; Inflammation of joints.<br />&bull; Muscles feeling stiff.<br />&bull; Worsening of the symptoms of myasthenia gravis (abnormal muscle fatigue leading<br />to weakness and in serious cases paralysis).<br />Also, there have been very rare cases of the following side effects reported following<br />treatment with other quinolone antibiotics, which might possibly also occur during<br />treatment with Maxim&trade;:<br />&bull; Increased blood sodium levels.<br />&bull; Increased blood calcium levels.<br />&bull; A special type of reduced red blood cell count (haemolytic anaemia).<br />&bull; Muscle reactions with muscle cell damage.<br />&bull; Increased sensitivity of the skin to sunlight or UV light.<br />If you get any side effects, talk to your doctor or pharmacist. This includes any side<br />effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not store above 30 &deg;C.<br />Do not use this medicine after the expiry date stated on the blister and carton.<br />The expiry date refers to the last day of the month.<br />Store in the original package in order to protect from moisture.<br />Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will<br />help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What MaximTM contains<br />- The active substance is moxifloxacin. Each film-coated tablet contains 400 mg<br />moxifloxacin as hydrochloride.<br />- The other ingredients are croscarmellose sodium, magnesium stearate, maize starch,<br />microcrystalline cellulose, opadry white, propylene glycol and purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Maxim™ tablets: White to off-white, oblong shaped, biconvex, film coated tablets
engraved with 'JP108' on one side and plain on the other side.
Maxim™ 400mg tablets available in packs of 5 & 7 film coated tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Ltd., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>على مادة فعالة تسمى موكسيفلوكساسين والتي تنتمي إلى فئة من المضادات الحيوية &trade; يحتوي ماكسيم<br />عن طريق قتل البكتيريا المسببة للعدوى. &trade; تسمى فلوروكينولون. يعمل ماكسيم<br />للمرضى من عمر ۱۸ عام فأكثر لعلاج العدوى البكتيرية التالية عندما تحدث بسبب &trade; يستخدم ماكسيم<br />بكتيريا تكون مادة الموكسيفلوكساسين فعالة ضدها.<br />لعلاج أنواع العدوى هذه فقط عندما يتعذر إستخدام المضادات الحيوية المعتادة &trade; يجب أن يستخدم ماكسيم<br />أو لا تعمل بالشكل المطلوب:<br />- عدوى الجيوب الأنفية، التدهور المفاجئ لالتهاب الممرات الهوائية طويل الأمد او عدوى الرئتين<br />(النيومونيا) المكتسبة من خارج المستشفى (عدا الحالات الشديدة).<br />- عدوى الجهاز التناسلي العلوي البسيطة إلى متوسطة عند الإناث (التهاب الحوض) بما في ذلك عدوى<br />قناة فالوب وعدوى الغشاء المخاطي للرحم.<br />وحده كافياً لعلاج أنواع العدوى هذه لذلك ينبغي على الطبيب أن يقوم بوصف مضاد &trade; قد لا يكون ماكسيم<br />عند علاج عدوى الجهاز التناسلي العلوى عند الإناث (انظر الجزء رقم &trade; حيوى آخر بجانب ماكسيم<br />.(&trade; ۲. قبل أن تستخدم ماكسيم<br />إذا حدث تحسن في حالات العدوى التالية بعد إستخدام محلول موكسيفلوكساسين للتسريب في الوريد فمن<br />لإكمال مدة العلاج: &trade; الوارد أن يصف لك الطبيب أقراص ماكسيم<br />- عدوى الرئتين (النيومونيا) المكتسبة خارج المستشفى، عدوى الجلد والأنسجة الرخوة أو في حالات<br />لا ينبغي أن تستخدم لبدء العلاج لأي نوع من التهابات الجلد &trade; عدوى الرئتين الشديدة. أقراص ماكسيم<br />والأنسجة الرخوة أو في عدوى الرئتين الشديدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اتصل بطبيبك إذا لم تكن متأكداً بشأن انتمائك لأحد الفئات المذكورة أدناه.<br />إذا &trade; لا تتناول ماكسيم<br />- إذا كان لديك حساسية ضد المادة الفعالة موكسيفلوكساسين أو أي من مكونات الدواء الأخرى (راجع<br />الجزء رقم ٦ في هذه النشرة)<br />- إذا كنتِ حاملاً أو مرضعة.<br />- إذا كان عمرك أقل من ۱۸ عام.<br />- إذا سبق لك الإصابة بمشاكل في الأوتار عند العلاج بمضادات حيوية من فئة الكينولون (انظر الجزء:<br />تحذيرات واحتياطات وكذلك الجزء رقم ٤ الخاص بالآثار الجانبية).<br />إذا كنت مولودا بهذه الحالات أو مصابا بها:<br />- حالات اختلال ايقاع القلب (تظهر من خلال رسم القلب، وهو تسجيل كهربائي للقلب).<br />- عدم توازن الأملاح في الدم (وبخاصة انخفاض مستوى البوتاسيوم و الماغنسيوم في الدم).<br />- البطء الشديد في إيقاع القلب (يسمى تباطؤ القلب).<br />- ضعف عضلة القلب (السكتة القلبية).<br />- إذا كان هناك تاريخ من حالات اختلال في إيقاع القلب.<br />أو<br />- إذا كنت تتناول أي أدوية أخرى تتسبب في تغيرات في رسم القلب (يرجى مراجعة الجزء الخاص بتناول<br />قد يتسبب في تغيرات في رسم القلب وهي &trade; الادوية الأخرى في هذه النشرة). وهذا بسبب أن ماكسيم<br />تأخر في توصيل الإشارات الكهربية). ) QT إستطالة فترة الإستقطاب<br />- إذا كان لديك مرض شديد في الكبد أو ارتفاع في إنزيمات الكبد (ترانزأمينيز) لأكثر من خمسة أضعاف<br />المعدل الطبيعي لها.<br />تحذيرات واحتياطات<br />&trade; تحدث إلى طبيبك قبل إستخدام ماكسيم<br />- إذا كنت قد تم تشخيصك مع توسيع أو &quot;انتفاخ&quot; في أحد الاوعية الدموية الكبيرة (الأبهر أو الأوعية<br />الدموية الطرفية الكبيرة.).<br />- إذا كنت قد عانيت من حدث سابق من تسلخ الأبهر (تمزق في جدار الأبهر).<br />- إذا كان لديك تاريخ عائلي من تمدد الأوعية الدموية الأبهري أو تسلخ الأبهر أو عوامل الخطر الأخرى<br />أو ظروف مهيئة (مثل اضطرابات النسيج الضام مثل متلازمة مارفان، متلازمة الأوعية الدموية<br />إهلرز-دانلوس ، أو اضطرابات الأوعية الدموية مثل تاكاياسو الشرايين، التهاب الشريان ذو الخلايا<br />العملاقة، مرض بهجت أو ارتفاع ضغط الدم أو تصلب شرايين معروف).<br />إذا شعرت بألم شديد مفاجئ في بطنك أو صدرك أو ظهرك ، فانتقل فوراً إلى غرفة الطوارئ.<br />من مخطط كهربية القلب الخاص بك (رسم القلب) خاصة عند الإناث أو كبار &trade; - يمكن أن يغير ماكسيم<br />السن. إذا كنت تتناول أي دواء يقلل من مستوى البوتاسيوم في الدم فينبغى عليك استشارة الطبيب قبل<br />إذا وكذلك الجزء: إستخدام الأدوية الأخرى). &trade; راجع أيضا الجزء: لا تستخدم ماكسيم ) &trade; إستخدام ماكسيم<br />- إذا كنت تعاني من الصرع أو أي امراض أخرى تتسبب في حدوث تشنجات فينبغي عليك استشارة<br />.&trade; الطبيب قبل إستخدام ماكسيم<br />- إذا كنت مصاباً أو سبق لك الإصابة بأي من مشاكل الصحة العقلية فينبغي عليك استشارة الطبيب قبل<br />.&trade; إستخدام ماكسيم<br />- إذا كنت مصابا بمرض الوهن العضلي الوبيل (إجهاد غير طبيعي في العضلات يؤدي إلى الضعف وفي<br />قد يؤدي إلى تدهور الأعراض الخاصة &trade; بعض الحالات الخطيرة يؤدي إلى الشلل)، تناول ماكسيم<br />بالمرض. إذا كنت تعتقد أنك مصاب بهذا المرض استشر طبيبك على الفور.<br />- إذا كنت أنت أو أحد أفراد عائلتك مصابا بنقص في إنزيم سداسي فوسفات الجلوكوز النازع للهيدروجين<br />بالنسبة لك. &trade; (حالة وراثية نادرة)، اخبر طبيبك الذي سينصحك عن مدى ملائمة ماكسيم<br />- في حالات الإصابة بعدوى الجهاز التناسلي العلوي المصحوبة بمضاعفات عند الإناث (مثل تلك<br />المصحوبة بخراج في قناة فالوب أو المبايض او الحوض) والتي يعتبرها الطبيب من الحالات الضرورية<br />غير مناسب. &trade; التي يجب إستخدام علاج بطريق الوريد، يكون العلاج ب ماكسيم<br />- لعلاج عدوى الجهاز التناسلي العلوي المصحوبة بمضاعفات عند الإناث ينبغي على الطبيب أن يقوم<br />إذا لم يحدث تحسن في الأعراض بعد ۳ أيام يجب عليك .&trade; بوصف مضاد حيوي آخر بجانب ماكسيم<br />استشارة الطبيب.<br />&trade; عند إستخدام ماكسيم<br />- إذا شعرت بخفاق في القلب أو بنبضات قلب غير منتظمة خلال فترة العلاج يجب عليك إخبار الطبيب<br />على الفور.قد يطلب منك عمل رسم قلب لمعرفة إيقاع القلب.<br />- خطر التعرض لمشاكل في القلب يزيد مع زيادة الجرعة، لذا يجب الالتزام بالجرعة الموصى بها.<br />- هناك احتمال نادر في حدوث تفاعل تحسسي شديد ومفاجئ (صدمة تحسسية) حتى مع الجرعة الأولى.<br />تشتمل الأعراض على ضيق في الصدر، الشعور بالدوار، الغثيان ، الإغماء أو الشعور بالدوار عند<br />واستشر طبيبك على الفور. &trade; الوقوف. إذا حدث ذلك توقف عن إستخدام ماكسيم<br />التهاب شديد وسريع في الكبد قد يؤدي إلى فشل كبدي مهدد للحياة (بما في ذلك &trade; - قد يسبب ماكسيم<br />الحالات المميتة، راجع الجزء رقم ٤. الآثار الجانبية المحتملة). إذا شعرت فجأة بالتعب أو القئ أو كليهما<br />وكذلك إصفرار الجزء الأبيض من العين، بول داكن، حكة في الجلد، ميل للنزيف أو مرض في المخ بسبب<br />الكبد (أعراض انخفاض وظائف الكبد أو التهاب سريع ومفاجئ في الكبد)، يرجى الاتصال بالطبيب على<br />الفور قبل إستخدام المزيد من الأقراص.<br />- إذا حدث تفاعل جلدي أو تبثر/ تقشير في الجلد أو تفاعل مخاطي أو كليهما (انظر الجزء رقم ٤ . الآثار<br />الجانبية المحتملة)، اتصل بطبيبك على الفور قبل استكمال العلاج.<br />قد تتسبب في حدوث تشنجات. إذا حدث ذلك &trade; - المضادات الحيوية من فئة الكينولون بما فيها ماكسيم<br />توقف عن تناول الدواء واتصل بطبيبك على الفور.<br />بعد &trade; - قد تحدث أعراض اعتلال الأعصاب الطرفي المرتبط باستخدام الفلوروكينولونات بما فيها ماكسيم<br />وقت قصير من بدء العلاج، وربما يكون لا رجعة فيه. إذا ظهرت أعراض اعتلال الأعصاب المحيطية بما<br />فورا واتصل &trade; في ذلك الألم، حرقان، وخز، خدر و / أو حدوث ضعف ، يجب عليك إيقاف ماكسيم<br />بطبيبك.<br />- قد تحدث مشاكل في الصحة العقلية حتى عند إستخدام مضادات حيوية من فئة الكينولون بما في ذلك عند<br />لأول مرة. في بعض الحالات النادرة جداً قد يؤدي للإكتئاب أو مشكلات الصحة العقلية &trade; إستخدام ماكسيم<br />إلى أفكار انتحارية وسلوك مضر بالنفس مثل محاولات الانتحار (انظر الجزء رقم ٤ .الآثار الجانبية<br />المحتملة). إذا حدث لك هذا التفاعل توقف عن إستخدام الدواء واستشر طبيبك على الفور.<br />إذا أصبح الإسهال .&trade; - قد تصاب بالإسهال أثناء أو بعد إستخدام المضادات الحيوية بما في ذلك ماكسيم<br />حاداً أو مستمراً أو لاحظت ظهور دم أو مخاط في البراز، يجب عليك التوقف عن إستخدام الدواء<br />واستشارة الطبيب على الفور. لا يجب إستخدام الأدوية التي تبطئ أو توقف حركة الأمعاء.<br />ألم والتهاب في الأوتار خلال ٤۸ ساعة من إستخدام الدواء وحتى شهور عديدة بعد &trade; - قد يسبب ماكسيم<br />التوقف عن إستخدامه. تزداد احتمالية التهاب وتمزق الأوتار في حالات كبار السن أو في حالات المرضى<br />&trade; الذين يتعاطون الكورتيكوستيرودات. عند أول بادرة ألم أو التهاب يجب عليك التوقف عن تناول ماكسيم<br />وأرح الطرف المصاب واستشر طبيبك على الفور. ابتعد عن أي مجهود عضلى غير ضروري حيث أن<br />إذا وكذلك الجزء رقم &trade; ذلك قد يؤدي إلى زيادة إمكانية تمزق الأوتار (راجع الجزء: لا تستخدم ماكسيم<br />٤ .الآثار الجانبية المحتملة).<br />- في حالات كبار السن الذين يعانون من مشاكل في الكلى يجب التأكد من شرب كمية كافية عند تناول<br />إذا أصبت بجفاف فقد يزيد ذلك من امكانية التعرض لفشل كلوي. .&trade; ماكسيم<br />استشر طبيب متخصص ،&trade; - إذا لاحظت اضطراب في الرؤية أو إذا تأثرت عينك أثناء إستخدامك ماكسيم<br />في العيون على الفور (راجع الجزء : قيادة المركبات وتشغيل المعدات وكذلك الجزء رقم ٤ . الآثار<br />الجانبية المحتملة).<br />- المضادات الحيوية من فئة الكينولون قد تجعل جلدك أكثر حساسية لأشعة الشمس أو الأشعة فوق<br />البنفسجية. يجب عليك الابتعاد عن التعرض المستمر لأشعة الشمس أو أشعة الشمس القوية وينبغي كذلك<br />.&trade; عدم إستخدام الأسرَة الشمسية أو مصابيح الأشعة فوق البنفسجية عند إستخدام ماكسيم<br />في علاج الحروق الشديدة، عدوى الأنسجة العميقة، القدم السكري مع التهاب في نخاع &trade; - فعالية ماكسيم<br />العظام لم تثبت بعد.<br />الأطفال والمراهقين<br />لا تستخدم هذا الدواء مع الأطفال والمراهقين الأقل من ۱۸ عام لأن فعالية وأمان الدواء لهذه الفئات<br />إذا) &trade; العمرية لم تثبت بعد (انظر الجزء: لا تستخدم ماكسيم<br />إستخدام الأدوية الأخرى<br />أخبر طبيبك عن أي دواء آخر تتعاطاه الآن أو تناولته منذ فترة وجيزة أو تنوي تناوله.<br />كن على دراية بالآتي: ،&trade; بالنسبة ل ماكسيم<br />مع أي دواء آخر يؤثر على القلب فإن ذلك قد يؤدي إلى زيادة احتمالية حدوث &trade; - إذا كنت تتناول ماكسيم<br />جنبا إلى جنب مع هذه الأدوية: &trade; تغير في إيقاع القلب ولهذا لا تتناول ماكسيم<br />- الأدوية التي تنتمي إلى فئة مضادات عدم انتظام ضربات القلب (مثل: كينيدين، هيدروكينيدين،<br />ديسوبيراميد، أميودارون، سوتالول، دوفيتيلايد و ايبوتيلايد).<br />- مضادات الذهان ( مثل: فينوثيازين، بيموزيد، سيرتيندول، هالوبيريدول و سولتوبرايد).<br />- مضادات الاكتئاب ثلاثية الحلقات<br />- بعض مضادات الميكروبات (مثل: ساكوينافير، سارفولكساسين، اريثرومايسين عبر الوريد، بنتاميدين،<br />مضادات الملاريا وبخاصة هالوفانترين).<br />- بعض مضادات الهيستامين (مثل: تيرفينادين، أستيميزول و ميزولاستين).<br />- أدوية اخرى مثل (سيسابريد، فينكامين عبر الوريد، بيبريديل و دايفيمانيل).<br />- ينبغي عليك إخبار الطبيب إذا كنت تتناول أدوية تخفض من مستوى البوتاسيوم في الدم (مثل: بعض<br />مدرات البول، بعض الملينات والحقن الشرجية &quot;الجرعات العالية&quot;، الكورتيكوستيرودات &quot;أدوية مضادة<br />للالتهاب&quot;، أمفوتيريسين ب) أو تسبب بطء معدل ضربات القلب لأن هذا قد يؤدي إلى زيادة خطر حدوث<br />.&trade; اضطرابات خطيرة في ايقاع القلب أثناء إستخدام ماكسيم<br />- أي دواء يحتوي على ماغنسيوم ، ألومنيوم (مثل مضادات الحموضة في حالات عسر الهضم)، حديد،<br />.&trade; زنك أو دواء يحتوي على سوكرالفات (لعلاج اضطرابات المعدة) من الممكن أن يقلل من أثر ماكسيم<br />قبل أو بعد ٦ ساعات من تناول الأدوية الأخرى. &trade; قم بتناول أقراص ماكسيم<br />يوصى بعدم .&trade; يقلل من أثر ماكسيم &trade; - تناول أي دواء يحتوي على الفحم جنباً إلى جنب مع أقراص ماكسيم<br />&trade; إستخدام هذه الأدوية جنباً إلى جنب مع ماكسيم<br />- إذا كنت تتناول في الوقت الحالي أدوية ترقق الدم (مضادات التجلط الفموية مثل الوارفارين)، قد يكون<br />من الضروري أن يراقب الطبيب الوقت المستغرق لتجلط الدم لديك.<br />مع الطعام والشراب &trade; تناول ماكسيم<br />مع أو بدون الطعام بما في ذلك منتجات الألبان. &trade; يمكن تناول ماكسيم<br />الحمل والإرضاع والخصوبة<br />إذا كنت حاملاً أو مرضعة. &trade; لا تتناول ماكسيم<br />إذا كنت حاملاً أو مرضعة أو تشكين في كونك حاملاً او تخططين لذلك، يجب استشارة الطبيب قبل تناول<br />.&trade; ماكسيم<br />.&trade; الدراسات التي أجريت على الحيوانات لم تثبت حدوث خلل في الخصوبة عند إستخدام ماكسيم<br />قيادة المركبات وتشغيل الآلات<br />تشعر بالدوار أو تصاب بدوار الرأس وقد تشعر بفقدان مؤقت للإبصار أو قد تصاب &trade; ربما يجعلك ماكسيم<br />بالإغماء لفترة قصيرة. إذا حدث ذلك فلا تقم بقيادة السيارات أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۳. كيف تستخدم أقراص ماكسيم<br />تماما كما يخبرك الطبيب إذا لم تكن متأكدا قم بمراجعة الطبيب أو &trade; يجب عليك إستخدام أقراص ماكسيم<br />الصيدلي.<br />الجرعة الموصى بها للبالغين هي قرص مغلف ٤۰۰ ملجم مرة واحدة يومياً.<br />تستخدم عن طريق الفم. يجب بلع القرص كاملاً (لإخفاء الطعم المر) وذلك مع كمية &trade; أقراص ماكسيم<br />مع أو بدون الطعام. حاول أن تتناول الدواء في نفس &trade; وفيرة من أي سائل. يمكنك أن تتناول ماكسيم<br />التوقيت يومياً.<br />يمكن تناول نفس الجرعة بالنسبة للمرضى كبار السن، المرضى ذوي الوزن المنخفض للجسم، المرضى<br />الذين لديهم مشاكل في الكلى.<br />تتوقف على العدوى المسببة، سيكون العلاج كالتالى ما لم يطلب &trade; المدة التي ستتناول خلالها ماكسيم<br />الطبيب منك غير ذلك:<br />۱۰ أيام. - - حالات التدهور المفاجئ (تفاقم حاد) للالتهاب الشعبي المزمن : ٥<br />- لعدوى الرئتين (النيومونيا) ما عدا النيومونيا التي بدأت خلال فترة الإقامة بالمستشفى: ۱۰ أيام.<br />- العدوى البكتيرية الحادة للجيوب الأنفية: ۷ أيام.<br />- عدوى الجهاز التناسلي العلوي البسيطة إلى متوسطة عند الإناث (التهاب الحوض) بما في ذلك عدوى<br />قناة فالوب وعدوى الغشاء المخاطي للرحم: ۱٤ يوم.<br />لاستكمال العلاج الذي بدأ عن طريق التسريب في الوريد بمحلول &trade; حينما تستخدم أقراص ماكسيم<br />موكسيفلوكساسين تكون الجرعة الموصى بها هي:<br />۱٤ يوم . - - عدوى الرئتين (النيومونيا) المكتسبة خارج المستشفى: ۷<br />المغلفة عن طريق الفم &trade; أغلب المرضى المصابين بالنيومونيا يبدأون بالتحول لإستخدام أقراص ماكسيم<br />بعد ٤ أيام من بدء العلاج.<br />۲۱ يوم أغلب المرضى المصابين بعدوى الجلد والانسجة الرخوة - - عدوى الجلد والأنسجة الرخوة: ۷<br />المغلفة عن طريق الفم بعد ٦ أيام من بدء العلاج. &trade; يبدأون بالتحول لإستخدام أقراص ماكسيم<br />من المهم ان تستكمل مدة العلاج كاملة حتى لو شعرت بالتحسن بعد أيام قليلة. إذا توقفت عن إستخدام<br />بشكل مبكر جداً عن المخطط له فقد لا يتم شفاؤك من العدوى وقد تعود العدوى من جديد أو &trade; ماكسيم<br />تصبح العدوى أسوأ من السابق. أيضاً قد يتسبب ذلك في ان تصبح البكتيريا المسببة للعدوى مقاومة للمضاد<br />&trade; الحيوي ماكسيم<br />.(&trade; لا يجب تخطي الجرعة الموصى بها أو مدة العلاج (انظر الجزء رقم ۲ . قبل أن تستخدم ماكسيم<br />بكمية أكثر مما ينبغي &trade; إذا تناولت ماكسيم<br />إذا تناولت أكثر من الجرعة الموصوفة وهي قرص واحد يوميا فيجب عليك الحصول على مساعدة طبية<br />على الفور. اصطحب معك ما تبقى من الأقراص وكذلك العبوة والنشرة الداخلية حيث أن ذلك يسهل من<br />إجراءات تعرف الطبيب أو الصيدلي على الدواء.</p><p>إذا نسيت أن تتناول ماكسيم<br />إذا نسيت أن تتناول جرعتك في موعدها المعتاد فقم بتناولها فور أن تتذكر في نفس اليوم. إذا لم تتذكر في<br />نفس اليوم فقم بتناول الجرعة الخاصة باليوم التالي فقط. لا تتناول ضعف الجرعة لتعويض جرعة فائتة.<br />إذا كنت غير متأكد بشأن الخطوات الواجب عليك اتخاذها، قم باستشارة الطبيب أو الصيدلي.<br />&trade; إذا توقفت عن تناول أقراص ماكسيم<br />إذا توقفت عن تناول الدواء بشكل مبكر جداً عن المخطط له فقد لا تُشفى بشكل كامل. أخبر طبيبك إذا كنت<br />ترغب في التوقف عن تناول الدواء قبل انتهاء المدة المحددة.<br />إذا كان لديك المزيد من الأسئلة حول كيفية إستخدام هذا الدواء، استشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>في تأثيرات جانبية ولكنها لا تصيب كل الأشخاص. &trade; كما هو الحال مع كل الأدوية، يمكن أن يتسبب ماكسيم<br />.&trade; الآثار الجانبية التالية تمت ملاحظتها خلال فترة العلاج ب ماكسيم<br />تحدث هذه الآثار الجانبية بتكرار معين يمكن تعريفه كالتالي:<br />- شائع: قد يصاب بها شخص من أصل ۱۰ يستخدمون الدواء.<br />- غير شائع: قد يصاب بها شخص من أصل ۱۰۰ يستخدمون الدواء.<br />- نادر: قد يصاب بها شخص من أصل ۱۰۰۰ يستخدمون الدواء.<br />- نادر جدا: قد يصاب بها شخص من أصل ۱۰۰۰۰ يستخدمون الدواء.<br />(&trade; الجهاز القلبي (انظر الجزء رقم ۲ . ما تحتاج أن تعرفه قبل أن تستخدم ماكسيم<br />- شائع: تغير في ايقاع القلب يظهر في مخطط كهربية القلب (رسم القلب) عند المرضى ممن لديهم<br />انخفاض في نسبة البوتاسيوم في الدم.<br />- غير شائع: قد تغير في ايقاع القلب يظهر في مخطط كهربية القلب (رسم القلب)، خفقان، عدم انتظام<br />وسرعة في ضربات القلب، تغيرات حادة في ايقاع القلب، ألم في الصدر (الذبحة الصدرية).<br />- نادر: ايقاع سريع غير طبيعي للقلب، إغماء.<br />- نادر جدا: ايقاع غير طبيعي للقلب، عدم انتظام ضربات القلب بشكل يهدد الحياة، توقف ضربات القلب.<br />الآثار الجانبية الشائعة<br />- العدوى التي تسببها البكتيريا والفطريات المقاومة (مثل عدوى الفم والمهبل التي تسببها فطريات الكانديدا<br />&quot;القلاع&quot;).<br />- الصداع.<br />- الدوار.<br />- الغثيان.<br />- القئ.<br />- ألم في المعدة.<br />- إسهال.<br />- زيادة تركيز انزيم كبدي مميز في الدم (ترانزأمينيز).<br />الآثار الجانبية غير الشائعة<br />- تفاعل تحسسي.<br />- انخفاض عدد خلايا الدم الحمراء (أنيميا).<br />- انخفاض عدد خلايا الدم البيضاء.<br />.(neurophils - - انخفاض لنوع معين لعدد خلايا دم بيضاء (العدلات<br />- انخفاض أو زيادة في عدد خلايا دم مميزة ضرورية في عملية التجلط.<br />.(eosinophils - - زيادة في لنوع معين لعدد خلايا دم بيضاء (الحمضات<br />- انخفاض في تجلط الدم.<br />- زيادة الدهون في الدم.<br />- الشعور بالقلق، عدم الراحة، الهياج.<br />- الشعور بالوخز أو التنميل أو كليهما.<br />- تغيرات في حاسة التذوق (في بعض الحالات النادرة جدا يحدث فقدان لحاسة التذوق).<br />- الشعور بالارتباك و التوهان.<br />- مشاكل في النوم (الأرق أو النعاس).<br />- الرعاش.<br />- الشعور بالدوار (الدوران أو السقوط).<br />- مشاكل في الرؤية (تشمل ازدواج أو عدم وضوح الرؤية).<br />- توسع في الأوعية الدموية (احمرار).<br />- صعوبة في التنفس (تشمل ذلك حالات الربو).<br />- ضعف الشهية للطعام.<br />- خروج ريح وإمساك.<br />- اضطراب في المعدة (عسر هضم أو حرقة في المعدة).<br />- التهاب في المعدة.<br />- زيادة تركيز انزيم هضمي مميز في الدم (أميليز).<br />زيادة نسبة البيليروبين ،(&quot;LDH&quot; - مشاكل في وظائف الكبد (تشمل زيادة نسبة أنزيم كبدي مميز في الدم<br />في الدم، زيادة نسبة انزيم كبدي مميز في الدم &quot;جاما جلوتاميل ترانسفيريز أو الفوسفاتيز القلوي أو كليهما&quot;.<br />- حكة، طفح، جفاف جلدي، أرتيكاريا.<br />- ألم في المفاصل والعضلات.<br />- الجفاف.<br />- الشعور بالتعب (ضعف أو إجهاد)، ألم ووجع في الظهر أو الصدر أو الحوض أو الأطراف.<br />- التعرق.<br />الآثار الجانبية النادرة<br />- تفاعل تحسسي حاد ومفاجئ بما في ذلك الصدمة التحسسية المهددة للحياة ( ضيق في التنفس، انخفاض<br />في ضغط الدم، نبض سريع)، التورم (بما في ذلك تورم الممرات الهوائية المهدد للحياة).<br />- إسهال حاد مصحوب بدم أو مخاط أو كليهما (التهاب القولون المصاحب لتناول المضادات الحيوية بما في<br />ذلك التهاب القولون الغشائي الكاذب).<br />- الصفراء (اصفرار الجلد والجزء الأبيض من العين)، التهاب الكبد.<br />- ألم وتورم في الأوتار (التهاب الأوتار).<br />- زيادة نسبة السكر في الدم.<br />- زيادة نسبة حمض اليوريك في الدم.<br />- زيادة في التفاعل العاطفي.<br />- الاكتئاب (في بعض الحالات النادرة جدا قد يؤدي إلى محاولة الإضرار بالنفس مثل التفكير الانتحاري أاو<br />محاولات الانتحار أو كليهما).<br />- الهلوسة.<br />- مشاكل في الإحساس في الجلد.<br />- تغير في حاسة الشم (تشمل فقدان حاسة الشم).<br />- أحلام غير معتادة.<br />- مشاكل في الاتزان والتناسق (بسبب الدوار).<br />- تشنجات.<br />- اضطراب في التركيز.<br />- مشاكل في النطق.<br />- فقدان جزئي أو كلي للذاكرة.<br />- متاعب مصاحبة للجهاز العصبي مثل الألم، الحرقان، الوخز، التنميل مع أو بدون ضعف في الأطراف<br />- طنين أو ضوضاء في الأذن، مشاكل في السمع بما في ذلك الصمم (عادة قابل أن ينعكس مرة أخرى)<br />- ارتفاع أو انخفاض في ضغط الدم.<br />- صعوبة في البلع.<br />- التهاب في الفم.<br />- تقلصات عضلية أو وخز.<br />- ضعف في العضلات.<br />- مشاكل في الكلى (تشمل زيادة في بعض نتائج الاختبارات المعملية مثل اليوريا والكرياتنينين)، الفشل<br />الكلوي.<br />- تورم في (الأيدي/ الأقدام/ الكاحل/ الشفاة / الفم/ الحلق).<br />الآثار الجانبية النادرة جداً<br />- التهاب حاد في الكبد قد يؤدي إلى فشل كبدي مهدد لحياة (بما في ذلك الحالات المميتة).<br />- تغيرات في الجلد والأغشية المخاطية (بثور مؤلمة في الفم/الأنف أو في القضيب/المهبل)، متلازمة ستيفن<br />جونسون ،تحلل الجلد التسممي (حالات تهدد الحياة).<br />- تمزق في الأوتار.<br />- زيادة في تجلط الدم، انخفاض معتبر في خلايا دم بيضاء تسمى المحببات(ندرة المحببات<br />.(agranulocytosis<br />- شعور بالانفصال عن النفس (الشعور وكأنك لست أنت).<br />- الشعور بالتعب النفسي (عادة ما يؤدي إلى محاولة إيذاء النفس مثل التفكير الانتحاري أو محاولات<br />الانتحار).<br />- فقدان مؤقت للرؤية.<br />- الشعور بزيادة حساسية الجلد.<br />- التهاب المفاصل.<br />- الشعور بتيبس في العضلات.<br />- تدهور أعراض مرض الوهن العضلي الوبيل (اجهاد عضلي غير طبيعي يؤدي إلى الضعف وقد يؤدي<br />في بعض الحالات الخطيرة إلى الشلل).<br />أيضا هناك بعض الحالات النادرة جداً للآثار الجانبية التالية والتي حدثت عند إستخدام مضادات حيوية<br />.&trade; أخرى من فئة الكينولون ومن المحتمل أن تحدث أيضا عند إستخدام ماكسيم<br />- زيادة مستوى الصوديوم في الدم.<br />- زيادة مستوى الكالسيوم في الدم.<br />- نوع مميز من نقص عدد خلايا الدم الحمراء (فقر الدم الانحلالي).<br />- تفاعلات عضلية مع تلف في خلايا العضلات.<br />- زيادة حساسية الجلد للاشعة فوق البنفسجية.<br />إذا وصلت أي من هذه الآثار الجانبية لدرجة الخطورة أو لاحظت ظهور آثار جانبية أخرى لم تذكر في هذه<br />النشرة، يرجى استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />م. &ordm; &bull; يحفظ فى درجة حرارة لا تزيد عن ۳۰<br />&bull; قم بالتخزين في العبوة الأصلية للحماية من الرطوبة.<br />بعد انتهاء فترة صلاحيتها المكتوب على الشرائط وعلى العلبة. &trade; &bull; لا تتناول أقراص ماكسيم<br />&bull; إسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. لا ينبغي التخلص من الأدوية عبر<br />إلقائها فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في هذه الأقراص هي الموكسيفلوكساسين. كل قرص مغلف يحتوي على ٤۰۰ ملجم من<br />الموكسيفلوكساسين في شكل هيدروكلوريد.<br />المكونات الاخرى هي:<br />المكونات الأخرى هي كروسكارميلوز الصوديوم، ستيرات المغنيسيوم، نشا الذرة، سيليلوز دقيق التبلور،<br />أبادرى أبيض، بروبيلين جليكول و ماء منقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>وما هي محتويات العبوة &trade; كيف تبدو أقراص ماكسيم<br />أقراص : لونها أبيض إلى مائل للأبيض، مستطيلة، محدبة الوجهين مغلفة، محفور على أحد &trade; ماكسيم<br />ومستوية علي الجانب الآخر. &#39;JP الوجهين &#39; 108<br />٤۰۰ ملجم أقراص متوفرة في عبوات تحتوي ٥ أقرص مغلفة أو ۷ أقرص مغلفة. &trade; ماكسيم<br />قد لا تكون كل أحجام العبوات مطروحة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسويق و المصنع:<br />شركة مصنع جمجوم للأدوية المحدودة، جدة، المملكة العربية السعودية.<br />+۹٦٦-۱۲- ۹٦٦ + فاكس: ٦۰۸۱۲۲۲ -۱۲- هاتف: ٦۰۸۱۱۱۱<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />- المركز الوطني للتيقظ و السلامة الدوائية<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات. o<br />۲۳٤۰-۲۳٥٦- ۹٦٦ + تحويلة: ۲۳۱۷ -۱۱- هاتف: ۲۰۳۸۲۲۲ o<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : بريد إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&bull; دول الخليج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Maxim 400 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablet contains 400 mg Moxifloxacin (as hydrochloride).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablet
White to off-white, oblong shaped, biconvex, about 7.0 x 20.0 mm in dimemension, film coated tablets engraved with 'JP108' on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Moxifloxacin 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to Moxifloxacin (see sections 4.4, 4.8 and 5.1). Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed:<br />- Acute bacterial sinusitis (adequately diagnosed)<br />- Acute exacerbations of chronic bronchitis (adequately diagnosed)<br />- Community acquired pneumonia, except severe cases<br />- Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess.<br />Moxifloxacin 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing Moxifloxacin resistance of Neisseria gonorrhoeae unless Moxifloxacin -resistant Neisseria gonorrhoeae can be excluded (see sections 4.4 and 5.1).</p><p>Moxifloxacin 400 mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous Moxifloxacin for the following indications:<br />- Community-acquired pneumonia<br />- Complicated skin and skin structure infections<br />Moxifloxacin 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community-acquired pneumonia.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology (adults)<br />The recommended dose is one 400 mg film-coated tablet once daily.<br />Renal/hepatic impairment<br />No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).<br />There is insufficient data in patients with impaired liver function (see section 4.3).<br />Other special populations<br />No adjustment of dosage is required in the elderly and in patients with low bodyweight.<br />Paediatric population<br />Moxifloxacin is contraindicated in children and adolescents (&lt; 18 years). Efficacy and safety of Moxifloxacin in children and adolescents have not been established (see section 4.3). Method of administration<br />The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.</p><p>Duration of administration<br />Moxifloxacin 400 mg film-coated tablets should be used for the following treatment durations:<br />- Acute exacerbation of chronic bronchitis<br />5 - 10 days<br />- Community acquired pneumonia<br />10 days<br />- Acute bacterial sinusitis<br />7 days<br />- Mild to moderate pelvic inflammatory disease<br />14 days<br />Moxifloxacin 400 mg film-coated tablets have been studied in clinical trials for up to 14 days treatment.<br />Sequential (intravenous followed by oral) therapy<br />In clinical studies with sequential therapy most patients switched from intravenous to oral therapy within 4 days (community-acquired pneumonia) or 6 days (complicated skin and skin structure infections). The recommended total duration of intravenous and oral treatment is 7 -14 days for community-acquired pneumonia and 7 -21 days for complicated skin and skin structure infections<br />The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to Moxifloxacin , other quinolones or to any of the excipients listed in section 6.1.
- Pregnancy and lactation (see section 4.6).
- Patients below 18 years of age.
- Patients with a history of tendon disease/disorder related to quinolone treatment.
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to Moxifloxacin , in the form of QT prolongation. For reasons of drug safety, Moxifloxacin is therefore contraindicated in patients with:
- Congenital or documented acquired QT prolongation
- Electrolyte disturbances, particularly in uncorrected hypokalaemia
- Clinically relevant bradycardia
- Clinically relevant heart failure with reduced left-ventricular ejection fraction
- Previous history of symptomatic arrhythmias Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5).
Due to limited clinical data, Moxifloxacin is also contraindicated in patients with impaired liver function (Child Pugh C) and in patients with transaminases increase > 5fold ULN.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The benefit of Moxifloxacin treatment especially in infections with a low degree of severity should be balanced with the information contained in the warnings and precautions section. Prolongation of QTc interval and potentially QTc-prolongation-related clinical conditions<br />Moxifloxacin has been shown to prolong the QTc interval on the electrocardiogram in some patients. In the analysis of ECGs obtained in the clinical trial program, QTc prolongation with Moxifloxacin was 6 msec &plusmn; 26 msec, 1.4% compared to baseline. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.<br />Medication that can reduce potassium levels should be used with caution in patients receiving Moxifloxacin (see also sections 4.3 and 4.5).<br />Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients), such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. torsade de pointes) and cardiac arrest (see also section 4.3). The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded.<br />If signs of cardiac arrhythmia occur during treatment with Moxifloxacin , treatment should be stopped and an ECG should be performed. Hypersensitivity/allergic reactions<br />Hypersensitivity and allergic reactions have been reported for fluoroquinolones including Moxifloxacin after first administration. Anaphylactic reactions can progress to a life-threatening shock, even after the first administration. In these cases Moxifloxacin should be discontinued and suitable treatment (e.g. treatment for shock) initiated.&nbsp;Severe liver disorders<br />Cases of fulminant hepatitis potentially leading to liver failure (including fatal cases) have been reported with Moxifloxacin (see section 4.8). Patients should be advised to contact their doctor prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy.<br />Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur. Serious bullous skin reactions<br />Cases of bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with Moxifloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur. Patients predisposed to seizures<br />Quinolones are known to trigger seizures. Use should be with caution in patients with CNS disorders or in the presence of other risk factors which may predispose to seizures or lower the seizure threshold. In case of seizures, treatment with Moxifloxacin should be discontinued and appropriate measures instituted. Peripheral neuropathy<br />Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesias, hypoaesthesias, dysaesthesias, or weakness have been reported in patients receiving quinolones including Moxifloxacin . Patients under treatment with Moxifloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop (see section 4.8). Psychiatric reactions<br />Psychiatric reactions may occur even after the first administration of quinolones, including Moxifloxacin . In very rare cases depression or psychotic reactions have progressed to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4.8). In the event that the patient develops these reactions, Moxifloxacin should be discontinued and appropriate measures instituted.</p><p>Caution is recommended if Moxifloxacin is to be used in psychotic patients or in patients with history of psychiatric disease. Antibiotic-associated diarrhea incl. colitis<br />Antibiotic-associated diarrhea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and Clostridium difficult-associated diarrhea, has been reported in association with the use of broad spectrum antibiotics including Moxifloxacin and may range in severity from mild diarrhea to fatal colitis. Therefore it is important to consider this diagnosis in patients who develop serious diarrhea during or after the use of Moxifloxacin . If AAD or AAC is suspected or confirmed, ongoing treatment with antibacterial agents, including Moxifloxacin , should be discontinued and adequate therapeutic measures should be initiated immediately. Furthermore, appropriate infection control measures should be undertaken to reduce the risk of transmission. Drugs inhibiting peristalsis are contraindicated in patients who develop serious diarrhea. Patients with myasthenia gravis<br />Moxifloxacin should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated. Tendon inflammation, tendon rupture<br />Tendon inflammation and rupture (especially Achilles tendon), sometimes bilateral, may occur with quinolone therapy including Moxifloxacin , even within 48 hours of starting treatment and have been reported up to several months after discontinuation of therapy. The risk of tendinitis and tendon rupture is increased in elderly patients and in those treated concurrently with corticosteroids. At the first sign of pain or inflammation, patients should discontinue treatment with Moxifloxacin , rest the affected limb(s) and consult their doctor immediately in order to initiate appropriate treatment (e.g. immobilisation) for the affected tendon. (see sections 4.3 and 4.8).. Patients with renal impairment<br />Elderly patients with renal disorders should use Moxifloxacin with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure. Vision disorders<br />If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p>Dysglycemia<br />As with all fluoroquinolones, disturbances in blood glucose, including both hypoglycemia and hyperglycemia have been reported with Moxifloxacin . In Moxifloxacin -treated patients, dysglycemia occurred predominantly in elderly diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g. sulfonylurea) or with insulin. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8). Prevention of photosensitivity reactions<br />Quinolones have been shown to cause photosensitivity reactions in patients. However, studies have shown that Moxifloxacin has a lower risk to induce photosensitivity. Nevertheless patients should be advised to avoid exposure to either UV irradiation or extensive and/or strong sunlight during treatment with Moxifloxacin . Patients with glucose-6-phosphate dehydrogenase deficiency<br />Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. Therefore, Moxifloxacin should be used with caution in these patients. Patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Patients with pelvic inflammatory disease<br />For patients with complicated pelvic inflammatory disease (e.g. associated with a tubo-ovarian or pelvic abscess), for whom an intravenous treatment is considered necessary, treatment with Moxifloxacin 400 mg film-coated tablets is not recommended.<br />Pelvic inflammatory disease may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae. Therefore in such cases empirical Moxifloxacin should be co-administered with another appropriate antibiotic (e.g. a cephalosporin) unless Moxifloxacin -resistant Neustria gonorrhoeae can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered. Patients with special cSSSi<br />Clinical efficacy of intravenous Moxifloxacin in the treatment of severe burn infections, fasciitis and diabetic foot infections with osteomyelitis has not been established.</p><p>Interference with biological tests<br />Moxifloxacin therapy may interfere with the Mycobacterium spp. culture test by suppression of mycobacterial growth causing false negative results in samples taken from patients currently receiving Moxifloxacin . Patients with MRSA infections<br />Moxifloxacin is not recommended for the treatment of MRSA infections. In case of a suspected or confirmed infection due to MRSA, treatment with an appropriate antibacterial agent should be started (see section 5.1). Paediatric population<br />Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of Moxifloxacin in children and adolescents &lt; 18 years is contraindicated (see section 4.3).<br />Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.<br />Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or<br />aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection ( e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, hypertension, known atherosclerosis).<br />In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions with medicinal products<br />An additive effect on QT interval prolongation of Moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. Therefore, co-administration of Moxifloxacin with any of the following medicinal products is contraindicated (see also section 4.3):<br />- anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)&nbsp;- anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)<br />- antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)<br />- tricyclic antidepressive agents<br />- certain antimicrobial agents (saquinavir, sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine)<br />- certain antihistaminics (terfenadine, astemizole, mizolastine)<br />- others (cisapride, vincamine IV, bepridil, diphemanil).<br />Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels (e.g. loop and thiazide-type diuretics, laxatives and enemas [high doses], corticosteroids, amphotericin B) or medication that is associated with clinically significant bradycardia.<br />An interval of about 6 hours should be left between administration of agents containing bivalent or trivalent cations (e.g. antacids containing magnesium or aluminium, didanosine tablets, sucralfate and agents containing iron or zinc) and administration of Moxifloxacin .<br />Concomitant administration of charcoal with an oral dose of 400 mg Moxifloxacin led to a pronounced prevention of drug absorption and a reduced systemic availability of the drug by more than 80%. Therefore, the concomitant use of these two drugs is not recommended (except for overdose cases, see also section 4.9).<br />After repeated dosing in healthy volunteers, Moxifloxacin increased Cmax of digoxin by approximately 30% without affecting AUC or trough levels. No precaution is required for use with digoxin.<br />In studies conducted in diabetic volunteers, concomitant administration of oral Moxifloxacin with glibenclamide resulted in a decrease of approximately 21% in the peak plasma concentrations of glibenclamide. The combination of glibenclamide and Moxifloxacin could theoretically result in a mild and transient hyperglycaemia. However, the observed pharmacokinetic changes for glibenclamide did not result in changes of the pharmacodynamic parameters (blood glucose, insulin). Therefore no clinically relevant interaction was observed between Moxifloxacin and glibenclamide.<br />Changes in INR<br />A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins. The infectious and inflammatory conditions, age and general&nbsp;status of the patient appear to be risk factors. Under these circumstances, it is difficult to evaluate whether the infection or the treatment caused the INR (international normalised ratio) disorder. A precautionary measure would be to more frequently monitor the INR. If necessary, the oral anticoagulant dosage should be adjusted as appropriate.<br />Clinical studies have shown no interactions following concomitant administration of Moxifloxacin with: ranitidine, probenecid, oral contraceptives, calcium supplements, morphine administered parent rally, theophylline, cyclosporine or itraconazole.<br />In vitro studies with human cytochrome P450 enzymes supported these findings. Considering these results a metabolic interaction via cytochrome P450 enzymes is unlikely. Interaction with food<br />Moxifloxacin has no clinically relevant interaction with food including dairy products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of Moxifloxacin in human pregnancy has not been evaluated.. Animal studies have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, Moxifloxacin must not be used in pregnant women (see section 4.3). Breastfeeding<br />There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of Moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during Moxifloxacin therapy (see section 4.3). Fertility<br />Animal studies do not indicate impairment of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Moxifloxacin on the ability to drive and use machines have been performed. However, fluoroquinolones including Moxifloxacin may result in an impairment of the patient&#39;s ability to drive or operate machinery due to CNS reactions (e.g. dizziness; acute, transient loss of vision, see section 4.8) or acute and short lasting loss of consciousness (syncope, see section 4.8). Patients should be advised to see how they react to Moxifloxacin before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Adverse reactions based on all clinical trials with Moxifloxacin &nbsp;400 mg (oral and sequential therapy) sorted by frequencies are listed below:</p><p style="text-align:justify">Apart from nausea and diarrhea all adverse reactions were observed at frequencies below 3%.</p><p style="text-align:justify">Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Frequencies are defined as:</p><p style="text-align:justify">- Common (&ge; 1/100 to &lt; 1/10)</p><p style="text-align:justify">- Uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p style="text-align:justify">- Rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p style="text-align:justify">- Very rare (&lt; 1/10,000)</p><table cellspacing="0" cellpadding="0" border="1" style="width:504.75pt"><tbody><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>System Organ Class (MedDRA)</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Common</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Uncommon</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Rare</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Very Rare</strong></p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Infections and infestations</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Superinfections due to resistant bacteria or fungi e.g. oral and vaginal candidiasis</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Blood and lymphatic system disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Anaemia</p><p style="text-align:justify">Leucopenia(s)</p><p style="text-align:justify">Neutropenia</p><p style="text-align:justify">Thrombocytopenia</p><p style="text-align:justify">Thrombocythemia</p><p style="text-align:justify">Blood eosinophilia</p><p style="text-align:justify">Prothrombin time prolonged/INR increased</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Prothrombin level increased/INR decreased</p><p>Agranulocytosis</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Immune system disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Allergic reaction (see section 4.4)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Anaphylaxis incl. very rarely life-threatening shock (see section 4.4)</p><p>Allergic oedema / angiooedema (incl. laryngeal oedema, potentially life-threatening, see section 4.4)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Metabolism and nutrition disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Hyperlipidemia</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Hyperglycemia</p><p>Hyperuricemia</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Hypoglycemia</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Psychiatric disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Anxiety reactions</p><p style="text-align:justify">Psychomotor hyperactivity/ agitation</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Emotional lability</p><p>Depression (in very rare cases potentially culminating in self-injurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p><p>Hallucination</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Depersonalization</p><p>Psychotic reactions (potentially culminating in self- injurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Nervous system disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Headache</p><p style="text-align:justify">Dizziness</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Par- and Dysaesthesia</p><p>Taste disorders (incl. ageusia in very rare cases)</p><p>Confusion and disorientation</p><p>Sleep disorders (predominantly insomnia)</p><p>Tremor</p><p>Vertigo</p><p>Somnolence</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Hypoaesthesia</p><p>Smell disorders (incl. anosmia)</p><p>Abnormal dreams</p><p>Disturbed coordination (incl. gait disturbances, esp. due to dizziness or vertigo)</p><p>Seizures incl. grand mal convulsions (see section 4.4)</p><p>Disturbed attention</p><p>Speech disorders</p><p>Amnesia</p><p>Peripheral neuropathy and polyneuropathy</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Hyperaesthesia</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Eye disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Visual disturbances incl. diplopia and blurred vision (especially in the course of CNS reactions, see section 4.4)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Transient loss of vision (especially in the course of CNS reactions, see sections 4.4 and 4.7)</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Ear and labyrinth disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Tinnitus</p><p>Hearing impairment incl. deafness (usually reversible)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>&nbsp;</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Cardiac disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>QT prolongation in patients with hypokalaemia (see sections 4.3 and 4.4)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>QT prolongation (see section 4.4)</p><p>Palpitations</p><p>Tachycardia</p><p>Atrial fibrillation</p><p>Angina pectoris</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Ventricular tachyarrhythmias</p><p>Syncope (i.e., acute and short lasting loss of consciousness)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Unspecified arrhythmias</p><p>Torsade de Pointes (see section 4.4)</p><p>Cardiac arrest (see section 4.4)</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Vascular disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Vasodilatation</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Hypertension</p><p style="text-align:justify">Hypotension</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Dyspnea (including asthmatic conditions)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Gastrointestinal disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Nausea</p><p>Vomiting</p><p>Gastrointestinal and abdominal pains</p><p>Diarrhoea</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Decreased appetite and food intake</p><p>Constipation</p><p>Dyspepsia</p><p>Flatulence</p><p>Gastritis</p><p>Increased amylase</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Dysphagia</p><p>Stomatitis</p><p>Antibiotic associated colitis (incl. pseudo-membranous colitis, in very rare cases associated with life-threatening complications, see section 4.4)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>&nbsp;</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Hepatobiliary disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Increase in transaminases</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Hepatic impairment (incl. LDH increase)</p><p>Increased bilirubin</p><p>Increased gamma-glutamyl-transferase</p><p>Increase in blood alkaline phosphatase</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Jaundice</p><p>Hepatitis (predominantly cholestatic)</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Fulminant hepatitis potentially leading to life-threatening liver failure (incl. fatal cases, see section 4.4)</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Pruritus</p><p style="text-align:justify">Rash</p><p style="text-align:justify">Urticaria</p><p style="text-align:justify">Dry skin</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis (potentially life-threatening, see section 4.4)</p></td></tr><tr><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Arthralgia</p><p style="text-align:justify">Myalgia</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p style="text-align:justify">Tendonitis (see section 4.4)</p><p style="text-align:justify">Muscle cramp</p><p style="text-align:justify">Muscle twitching</p><p style="text-align:justify">Muscle weakness</p></td><td style="height:4.55pt; vertical-align:top; width:20.0%"><p>Tendon rupture (see section 4.4)</p><p>Arthritis</p><p>Muscle rigidity</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td></tr><tr><td style="height:65.15pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>Renal and urinary disorders</strong></p></td><td style="height:65.15pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:65.15pt; vertical-align:top; width:20.0%"><p>Dehydration</p></td><td style="height:65.15pt; vertical-align:top; width:20.0%"><p>Renal impairment (incl. increase in BUN and creatinine)</p><p>Renal failure (see section 4.4)</p></td><td style="height:65.15pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="height:104.5pt; vertical-align:top; width:20.0%"><p style="text-align:justify"><strong>General disorders and administration site conditions</strong></p></td><td style="height:104.5pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td><td style="height:104.5pt; vertical-align:top; width:20.0%"><p>Feeling unwell (predominantly asthenia or fatigue)</p><p>Painful conditions (incl. pain in back, chest, pelvic and extremities)</p><p>Sweating</p></td><td style="height:104.5pt; vertical-align:top; width:20.0%"><p>Oedema</p></td><td style="height:104.5pt; vertical-align:top; width:20.0%"><p style="text-align:justify">&nbsp;</p></td></tr></tbody></table><p style="text-align:justify">There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with Moxifloxacin : hypernatraemia, hypercalcaemia, haemolytic anaemia, rhabdomyolysis, photosensitivity reactions (see section 4.4).</p><p style="text-align:justify"><strong><u>To report any side effect(s):</u></strong></p><ul><li style="text-align:justify"><strong><em>Saudi Arabia:</em></strong></li></ul><p style="text-align:justify">The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-left:.75in; margin-right:0in; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p style="margin-left:.75in; margin-right:0in; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:.75in; margin-right:0in; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Toll free phone: 19999</p><p style="margin-left:.75in; margin-right:0in; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa</p><p style="margin-left:.75in; margin-right:0in; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website: www.sfda.gov.sa/npc</p><ul><li style="text-align:justify"><strong><em>Other GCC States:</em></strong></li></ul><p style="margin-left:.75in; margin-right:0in; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific countermeasures after accidental overdose are recommended. In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Concomitant administration of charcoal with a dose of 400 mg oral Moxifloxacin will reduce systemic availability of the drug by more than 80%. The use of charcoal early during absorption may be useful to prevent excessive increase in the systemic exposure to Moxifloxacin in cases of oral overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Quinolone antibacterials, fluoroquinolones, ATC code: J01MA14</p><p style="text-align:justify"><u>Mechanism of action</u></p><p style="text-align:justify">Moxifloxacin &nbsp;has <em>in vitro</em> activity against a wide range of Gram-positive and Gram-negative pathogens.</p><p style="text-align:justify">The bactericidal action of Moxifloxacin &nbsp;results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the <em>nor</em>A or <em>pmr</em>A genes seen in certain Gram-positive bacteria.</p><p style="text-align:justify">Pharmacodynamic investigations have demonstrated that Moxifloxacin &nbsp;exhibits a concentration dependent killing rate. Minimum bactericidal concentrations (MBC) were found to be in the range of the minimum inhibitory concentrations (MIC).</p><p style="text-align:justify"><u>Effect on the intestinal flora in humans</u></p><p style="text-align:justify">The following changes in the intestinal flora were seen in volunteers following oral administration of Moxifloxacin : <em>Escherichia coli</em>, <em>Bacillus</em> spp., <em>Enterococcus</em> spp., and <em>Klebsiella</em> spp. were reduced, as were the anaerobes <em>Bacteroides vulgatus</em>, <em>Bifidobacterium</em> spp., <em>Eubacterium</em> spp., and <em>Peptostreptococcus</em> spp.. For <em>Bacteroides fragilis</em> there was an increase. These changes returned to normal within two weeks.</p><p style="text-align:justify"><u>Mechanism of resistance</u></p><p style="text-align:justify">Resistance mechanisms that inactivate penicillins, cephalosporins, aminoglycosides, macrolides and tetracyclines do not interfere with the antibacterial activity of Moxifloxacin . Other resistance mechanisms such as permeation barriers (common in <em>Pseudomonas aeruginosa</em>) and efflux mechanisms may also effect susceptibility to Moxifloxacin .</p><p style="text-align:justify"><em>In vitro</em> resistance to Moxifloxacin &nbsp;is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Moxifloxacin &nbsp;is a poor substrate for active efflux mechanisms in Gram-positive organisms.</p><p style="text-align:justify">Cross-resistance is observed with other fluoroquinolones. However, as Moxifloxacin &nbsp;inhibits both topoisomerase II and IV with similar activity in some Gram-positive bacteria, such bacteria may be resistant to other quinolones, but susceptible to Moxifloxacin .</p><p style="text-align:justify"><u>Breakpoints</u></p><p style="text-align:justify">EUCAST clinical MIC and disk diffusion breakpoints for Moxifloxacin &nbsp;(01.01.2011):</p><table cellspacing="0" cellpadding="0" border="1" style="width:508.5pt"><tbody><tr><td style="height:7.3pt; vertical-align:top; width:50.0%"><p style="text-align:justify"><strong>Organism</strong></p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Susceptible</strong></p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Resistant</strong></p></td></tr><tr><td style="height:7.3pt; vertical-align:top; width:50.0%"><p style="text-align:justify"><em>Staphylococcus</em> spp.</p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p><p style="text-align:justify">&ge; 24 mm</p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&gt; 1 mg/l</p><p style="text-align:justify">&lt; 21 mm</p></td></tr><tr><td style="height:7.3pt; vertical-align:top; width:50.0%"><p style="text-align:justify"><em>S. pneumoniae</em></p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p><p style="text-align:justify">&ge; 22 mm</p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&gt; 0.5 mg/l</p><p style="text-align:justify">&ge; 22 mm</p></td></tr><tr><td style="height:7.3pt; vertical-align:top; width:50.0%"><p style="text-align:justify"><em>Streptococcus</em> Groups A, B, C, G</p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p><p style="text-align:justify">&ge; 18 mm</p></td><td style="height:7.3pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&gt; 1 mg/l</p><p style="text-align:justify">&lt; 15 mm</p></td></tr><tr><td style="height:41.5pt; vertical-align:top; width:50.0%"><p style="text-align:justify"><em>H. influenzae </em></p></td><td style="height:41.5pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p><p style="text-align:justify">&ge; 25 mm</p></td><td style="height:41.5pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p><p style="text-align:justify">&ge; 25 mm</p></td></tr><tr><td style="height:42.5pt; vertical-align:top; width:50.0%"><p style="text-align:justify"><em>M. catarrhalis</em></p></td><td style="height:42.5pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p><p style="text-align:justify">&ge; 23 mm</p></td><td style="height:42.5pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&gt; 0.5 mg/l</p><p style="text-align:justify">&lt; 23 mm</p></td></tr><tr><td style="height:41.5pt; vertical-align:top; width:50.0%"><p style="text-align:justify"><em>Enterobacteriaceae</em></p></td><td style="height:41.5pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p><p style="text-align:justify">&ge; 20 mm</p></td><td style="height:41.5pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&gt; 1 mg/l</p><p style="text-align:justify">&lt; 17 mm</p></td></tr><tr><td style="height:20.75pt; vertical-align:top; width:50.0%"><p style="text-align:justify">Non-species related breakpoints*</p></td><td style="height:20.75pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&le; 0.5 mg/l</p></td><td style="height:20.75pt; vertical-align:top; width:25.0%"><p style="text-align:justify">&gt; 1 mg/l</p></td></tr><tr><td colspan="3" style="height:84.0pt; vertical-align:top; width:100.0%"><p style="text-align:justify">* Non-species related breakpoints have been determined mainly on the basis of pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and are not for use with species where interpretative criteria remain to be determined.</p></td></tr></tbody></table><p style="text-align:justify"><u>Microbiological Susceptibility</u></p><p style="text-align:justify">The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought where the local prevalence of resistance is such that utility of the agent in at least some types of infections is questionable.</p><table cellspacing="0" cellpadding="0" border="1" style="width:507.55pt"><tbody><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>Aerobic Gram-positive micro-organisms</u></p><p style="text-align:justify"><em>Gardnerella vaginalis</em></p><p style="text-align:justify"><em>Staphylococcus aureus</em>* (methicillin-susceptible)</p><p style="text-align:justify"><em>Streptococcus agalactiae</em> (Group B)</p><p style="text-align:justify"><em>Streptococcus milleri</em> group* (<em>S. anginosus, S. constellatus and S. intermedius</em>)</p><p style="text-align:justify"><em>Streptococcus pneumoniae</em>*</p><p style="text-align:justify"><em>Streptococcus pyogenes</em>* (Group A)</p><p style="text-align:justify"><em>Streptococcus viridans </em>group<em> (S. viridans, S. mutans, S. mitis, S. sanguinis, S. salivarius, S. thermophilus)</em></p></td></tr><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>Aerobic Gram-negative micro-organisms</u></p><p style="text-align:justify"><em>Acinetobacter baumanii </em></p><p style="text-align:justify"><em>Haemophilus influenzae</em>*</p><p style="text-align:justify"><em>Haemophilus parainfluenzae</em>*</p><p style="text-align:justify"><em>Legionella pneumophila</em></p><p style="text-align:justify"><em>Moraxella (Branhamella) catarrhalis</em>*</p></td></tr><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>Anaerobic micro-organisms</u></p><p style="text-align:justify"><em>Fusobacterium</em> spp.</p><p style="text-align:justify"><em>Prevotella</em> spp.</p></td></tr><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>&ldquo;Other&rdquo; micro-organisms</u></p><p style="text-align:justify"><em>Chlamydophila (Chlamydia) pneumoniae</em>*</p><p style="text-align:justify"><em>Chlamydia trachomatis*</em></p><p style="text-align:justify"><em>Coxiella burnetii</em></p><p style="text-align:justify"><em>Mycoplasma genitalium</em></p><p style="text-align:justify"><em>Mycoplasma hominis</em></p><p style="text-align:justify"><em>Mycoplasma pneumoniae</em>*</p></td></tr><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>Aerobic Gram-positive micro-organisms</u></p><p style="text-align:justify"><em>Enterococcus faecalis*</em></p><p style="text-align:justify"><em>Enterococcus faecium* </em></p><p style="text-align:justify"><em>Staphylococcus aureus</em> (methicillin-resistant)<sup>+</sup></p></td></tr><tr><td style="height:7.8pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>Aerobic Gram-negative micro-organisms</u></p><p style="text-align:justify"><em>Enterobacter cloacae</em>*</p><p style="text-align:justify"><em>Escherichia coli</em>*</p><p style="text-align:justify"><em>Klebsiella pneumoniae</em>*<sup>#</sup></p><p style="text-align:justify"><em>Klebsiella oxytoca </em></p><p style="text-align:justify"><em>Neisseria gonorrhoeae*</em><sup>+</sup></p><p style="text-align:justify"><em>Proteus mirabilis</em>*</p></td></tr><tr><td style="height:66.45pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>Anaerobic micro-organisms</u></p><p style="text-align:justify"><em>Bacteroides fragilis*</em></p><p style="text-align:justify"><em>Peptostreptococcus</em> spp.*</p></td></tr><tr><td style="height:22.15pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="height:45.35pt; vertical-align:top; width:100.0%"><p style="text-align:justify"><u>Aerobic Gram-negative micro-organisms</u></p><p style="text-align:justify"><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="height:88.6pt; vertical-align:top; width:100.0%"><p style="text-align:justify">*Activity has been satisfactorily demonstrated in susceptible strains in clinical studies in the approved clinical indications.</p><p style="text-align:justify"><sup>#</sup>ESBL-producing strains are commonly resistant to fluoroquinolones</p><p style="text-align:justify"><sup>+</sup>Resistance rate &gt; 50% in one or more countries</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Absorption and Bioavailability</u></p><p style="text-align:justify">Following oral administration Moxifloxacin &nbsp;is rapidly and almost completely absorbed. The absolute bioavailability amounts to approximately 91%.</p><p style="text-align:justify">Pharmacokinetics are linear in the range of 50 - 800 mg single dose and up to 600 mg once daily dosing over 10 days. Following a 400 mg oral dose peak concentrations of 3.1 mg/l are reached within 0.5 - 4 h post administration. Peak and trough plasma concentrations at steady-state (400 mg once daily) were 3.2 and 0.6 mg/l, respectively. At steady-state the exposure within the dosing interval is approximately 30% higher than after the first dose.</p><p style="text-align:justify"><u>Distribution</u></p><p style="text-align:justify">Moxifloxacin &nbsp;is distributed to extravascular spaces rapidly; after a dose of 400 mg an AUC of 35 m∙gh/l is observed. The steady-state volume of distribution (Vss) is approximately 2 l/kg. <em>In vitro </em>and <em>ex vivo</em> experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug. Moxifloxacin &nbsp;is mainly bound to serum albumin.</p><p style="text-align:justify">The following peak concentrations (geometric mean) were observed following administration of a single oral dose of 400 mg Moxifloxacin :</p><p style="text-align:justify">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:496.9pt"><tbody><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify"><strong>Tissue</strong></p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify"><strong>Concentration</strong></p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify"><strong>Site: Plasma ratio</strong></p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Plasma</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">3.1 mg/l</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">-</p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Saliva</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">3.6 mg/l</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">0.75 - 1.3</p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Blister fluid</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">1.6<sup>1</sup> mg/l</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">1.7<sup>1</sup></p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Bronchial mucosa</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">5.4 mg/kg</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">1.7 - 2.1</p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Alveolar macrophages</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">56.7 mg/kg</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">18.6 - 70.0</p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Epithelial lining fluid</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">20.7 mg/l</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">5 - 7</p></td></tr><tr><td style="height:21.4pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Maxillary sinus</p></td><td style="height:21.4pt; vertical-align:top; width:33.0%"><p style="text-align:justify">7.5 mg/kg</p></td><td style="height:21.4pt; vertical-align:top; width:34.0%"><p style="text-align:justify">2.0</p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Ethmoid sinus</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">8.2 mg/kg</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">2.1</p></td></tr><tr><td style="height:21.4pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Nasal polyps</p></td><td style="height:21.4pt; vertical-align:top; width:33.0%"><p style="text-align:justify">9.1 mg/kg</p></td><td style="height:21.4pt; vertical-align:top; width:34.0%"><p style="text-align:justify">2.6</p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Interstitial fluid</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">1.0<sup>2</sup> mg/l</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">0.8 - 1.4<sup>2,3</sup></p></td></tr><tr><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">Female genital tract*</p></td><td style="height:20.45pt; vertical-align:top; width:33.0%"><p style="text-align:justify">10.2<sup>4</sup> mg/kg</p></td><td style="height:20.45pt; vertical-align:top; width:34.0%"><p style="text-align:justify">1.72<sup>4</sup></p></td></tr></tbody></table><p style="text-align:justify">* intravenous administration of a single 400 mg dose</p><p style="text-align:justify"><sup>1</sup> 10 h after administration</p><p style="text-align:justify"><sup>2</sup> unbound concentration</p><p style="text-align:justify"><sup>3</sup> from 3 h up to 36 h post dose</p><p style="text-align:justify"><sup>4</sup> at the end of infusion</p><p style="text-align:justify"><u>Biotransformation</u></p><p style="text-align:justify">Moxifloxacin &nbsp;undergoes Phase II biotransformation and is excreted via renal and biliary/faecal pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2). M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.</p><p style="text-align:justify">In clinical Phase I and <em>in vitro</em> studies no metabolic pharmacokinetic interactions with other drugs undergoing Phase I biotransformation involving cytochrome P450 enzymes were observed. There is no indication of oxidative metabolism.</p><p style="text-align:justify"><u>Elimination</u></p><p style="text-align:justify">Moxifloxacin &nbsp;is eliminated from plasma with a mean terminal half life of approximately 12 hours. The mean apparent total body clearance following a 400 mg dose ranges from 179 to 246 ml/min. Renal clearance amounted to about 24 - 53 ml/min suggesting partial tubular reabsorption of the drug from the kidneys.</p><p style="text-align:justify">After a 400 mg dose, recovery from urine (approximately 19% for unchanged drug, approximately 2.5% for M1, and approximately 14% for M2) and faeces (approximately 25% of unchanged drug, approximately 36% for M1, and no recovery for M2) totalled to approximately 96%.</p><p style="text-align:justify">Concomitant administration of Moxifloxacin &nbsp;with ranitidine or probenecid did not alter renal clearance of the parent drug.</p><p style="text-align:justify"><em>Elderly and patients with low body weight</em></p><p style="text-align:justify">Higher plasma concentrations are observed in healthy volunteers with low body weight (such as women) and in elderly volunteers.</p><p style="text-align:justify"><em>Renal impairment</em></p><p style="text-align:justify">The pharmacokinetic properties of Moxifloxacin &nbsp;are not significantly different in patients with renal impairment (including creatinine clearance &gt; 20 ml/min/1.73 m<sup>2</sup>). As renal function decreases, concentrations of the M2 metabolite (glucuronide) increase by up to a factor of 2.5 (with a creatinine clearance of &lt; 30 ml/min/1.73 m<sup>2</sup>).</p><p style="text-align:justify"><em>Hepatic impairment</em></p><p style="text-align:justify">On the basis of the pharmacokinetic studies carried out so far in patients with liver failure (Child Pugh A, B), it is not possible to determine whether there are any differences compared with healthy volunteers. Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers. There is insufficient experience in the clinical use of Moxifloxacin &nbsp;in patients with impaired liver function.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on the haematopoetic system (slight decreases in the number of erythrocytes and platelets) were seen in rats and monkeys. As with other quinolones, hepatotoxicity (elevated liver enzymes and vacuolar degeneration) was seen in rats, monkeys and dogs. In monkeys CNS toxicity (convulsions) occurred. These effects were seen only after treatment with high doses of Moxifloxacin or after prolonged treatment.<br />Moxifloxacin , like other quinolones, was genotoxic in in vitro tests using bacteria or mammalian cells. Since these effects can be explained by an interaction with the gyrase in bacteria and - at higher concentrations - by an interaction with the topoisomerase II in mammalian cells, a threshold concentration for genotoxicity can be assumed. In in vivo tests, no evidence of genotoxicity was found despite the fact that very high Moxifloxacin doses were used. Thus, a sufficient margin of safety to the therapeutic dose in man can be provided. Moxifloxacin was non-carcinogenic in an initiation-promotion study in rats.&nbsp;Many quinolones are photoreactive and can induce phototoxic, photomutagenic and photocarcinogenic effects. In contrast, Moxifloxacin was proven to be devoid of phototoxic and photogenotoxic properties when tested in a comprehensive programme of in vitro and in vivo studies. Under the same conditions other quinolones induced effects.<br />At high concentrations, Moxifloxacin is an inhibitor of the rapid component of the delayed rectifier potassium current of the heart and may thus cause prolongations of the QT interval. Toxicological studies performed in dogs using oral doses of &ge; 90 mg/kg leading to plasma concentrations &ge; 16 mg/l caused QT prolongations, but no arrhythmias. Only after very high cumulative intravenous administration of more than 50fold the human dose (&gt; 300 mg/kg), leading to plasma concentrations of &ge; 200 mg/l (more than 40fold the therapeutic level), reversible, non-fatal ventricular arrhythmias were seen.<br />Quinolones are known to cause lesions in the cartilage of the major diarthrodial joints in immature animals. The lowest oral dose of Moxifloxacin causing joint toxicity in juvenile dogs was four times the maximum recommended therapeutic dose of 400 mg (assuming a 50 kg bodyweight) on a mg/kg basis, with plasma concentrations two to three times higher than those at the maximum therapeutic dose.<br />Toxicity tests in rats and monkeys (repeated dosing up to six months) revealed no indication regarding an oculotoxic risk. In dogs, high oral doses (&ge; 60 mg/kg) leading to plasma concentrations &ge; 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.<br />Reproductive studies performed in rats, rabbits and monkeys indicate that placental transfer of Moxifloxacin occurs. Studies in rats (p.o. and i.v.) and monkeys (p.o.) did not show evidence of teratogenicity or impairment of fertility following administration of Moxifloxacin . A slightly increased incidence of vertebral and rib malformations was observed in foetuses of rabbits but only at a dose (20 mg/kg i.v.) which was associated with severe maternal toxicity. There was an increase in the incidence of abortions in monkeys and rabbits at human therapeutic plasma concentrations. In rats, decreased foetal weights, an increased prenatal loss, a slightly increased duration of pregnancy and an increased spontaneous activity of some male and female offspring was observed at doses which were 63 times the maximum recommended dose on a mg/kg basis with plasma concentrations in the range of the human therapeutic dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br /> Microcrystalline Cellulose (PH102)<br /> Maize Starch<br /> Croscarmelose Sodium<br /> Magnesium Stearate<br /> Opadry white (03H28604)<br /> Propylene Glycol<br /> Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years (36 Months)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maxim 400 mg Film coated Tablets packed in Alu-Alu Blister, packs of 5 and 7 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>